RxDoctor Payments Data

Kristin Lewis, MD

Internal Medicine · Edmond, OKNPI 1306130547

Payments from drug & device makers

$7,664in general payments, 2019–2025

Across 524 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$733
  • Novo Nordisk$680
  • Takeda Pharmaceuticals U.S.A., Inc.$548
  • Pfizer$520
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,650100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,664 in reported general payments places this provider in the 90th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$132,616
Medicare patients
618
Services billed
1,796

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide95$115,266
OzempicSemaglutide73$97,715
EliquisApixaban73$66,677
ZenpepLipase/Protease/Amylase18$64,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$53,971
JardianceEmpagliflozin36$49,384
TrulicityDulaglutide32$35,604
LinzessLinaclotide15$22,758
FarxigaDapagliflozin Propanediol22$21,765
Breo ElliptaFluticasone/Vilanterol25$20,384
RybelsusSemaglutide12$19,967
MyrbetriqMirabegron25$19,025
GemtesaVibegron20$16,566
EntrestoSacubitril/Valsartan18$11,470
BelsomraSuvorexant12$11,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,091$150,870127 claims
Novo NordiskOzempic, Rybelsus$680$117,68385 claims
GSKTrelegy Ellipta, Breo Ellipta$1,104$74,35492 claims
PfizerEliquis$520$66,67773 claims
Boehringer IngelheimJardiance$419$49,38436 claims
AstraZenecaFarxiga, Symbicort$733$27,04244 claims
AbbVieLinzess, Synthroid$483$24,83538 claims
Astellas Pharma US IncMyrbetriq$95$19,02525 claims
Sumitomo Pharma America, Inc.Gemtesa$119$16,56620 claims
MerckBelsomra$311$11,39812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →